Genes differentially expressed in bipolar disorder and/or schizophrenia
AssigneeThe Regents of the University of California
InventorsMarquis P. Vawter, Ling Shao
Life of this patent
Estimating the term…
Abstract
This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or bipolar disorder thereby providing prognostic and diagnostic markers for the disorder. In addition genes are identified whose dysregulation provides markers that allow diagnostic distinction between schizophrenia and bipolar disorder.
Claims32
A method of detecting the presence of or a predisposition to a psychiatric illness in a human, said method comprising:
- screening a biological sample from said human for increased or decreased expression of two or more genes listed in Table 6, where upregulation or downregulation (as indicated in Table 6) of expression of said two or more genes, is an indicator for the presence of, or predisposition to, a psychiatric illness.
4-5. (canceled)
8-18. (canceled)
(canceled)
23-25. (canceled)
27-29. (canceled)
31-33. (canceled)
A method of distinguishing between schizophrenia and bipolar disorder or between a predisposition to schizophrenia and bipolar disorder in a human, said method comprising:
- screening a biological sample from said human for increased or decreased expression of two or more genes listed in Table 1, and/or Table 10, and/or Table 2, and/or Table 9, where dysregulation of the expression of the gene(s) as indicated in Table 1 or Table 10, as compared to a control, indicates the presence of, or a predisposition to schizophrenia, and dysregulation of the expression of the gene(s) as indicated in Table 2 or Table 9, as compared to a control, indicates the presence of or a predisposition to bipolar disorder.
35-37. (canceled)
(canceled)
42-44. (canceled)
46-53. (canceled)
55-62. (canceled)
A method of screening for an agent that mitigates one or more symptoms of a psychiatric disorder, said method comprising:
- administering a test agent to a cell and/or a mammal;
- and
- detecting altered expression in said cell and/or mammal of two or more genes listed in Tables 1, 2, 6, 9, or 10, where upregulation or downregulation (as indicated in Tables 1, 2, 6, 9, or 10) of expression of said two or more genes, as compared to a control, is an indicator that said test agent has activity that mediates one or more symptoms of a psychiatric disorder.
65-70. (canceled)
72-89. (canceled)
Dependencies are inferred from the claim text.